FBR Capital analyst Andrew Berens reiterated an Underperform rating and slashed his price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE